Complete Filing Data
Grown Rogue International Inc. reported Cash And Cash Equivalents of $4.68 million for FY2024.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Grown Rogue International Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$10.7M | -$662.3K | $420.0K | -$1.0M | -$2.4M | -$9.5M | -$7.5M | -$302.4K | -$13.5M |
| General And Administrative Expense | $10.1M | $6.5M | $5.9M | $4.0M | $2.2M | $4.7M | $2.7M | $1.0M | $418.2K |
| Other Comprehensive Income | -$10.7M | -$666.9K | $400.7K | -$1.1M | -$2.5M | -$9.4M | -$7.5M | -$302.4K | $110.5K |
| Gross Profit | $13.4M | $2.4M | $8.1M | $6.1M | $1.8M | $852.6K | -$413.5K | $989.9K | |
| Profit Loss From Operating Activities | $1.1M | $4.3M | $957.1K | $701.6K | -$1.6M | -$7.6M | -$5.0M | -$138.9K | |
| Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity | -$11.3M | -$533.0K | $447.5K | -$2.4M | -$2.3M | -$9.3M | -$7.5M | -$302.4K | |
| Interest Expenses | $379.2K | $370.6K | $402.2K | $197.6K | $249.3K | $245.5K | $965.3K | $163.5K | |
| Gross Profit Excluding Fair Value Items | $13.9M | $11.9M | $8.5M | $5.2M | $1.8M | $989.0K | $42.9K | $4.4K | |
| Cost Of Finished Cannabis Inventory Sold | $12.8M | $11.2M | $9.2M | $4.0M | $2.2M | $2.9M | $1.9M | $151.7K | |
| Comprehensive Income Attributable To Owners Of Parent | -$11.3M | -$537.6K | $428.2K | -$2.5M | -$2.4M | -$9.2M | -$7.5M | -$302.4K | |
| Profit Loss Attributable To Noncontrolling Interests | $606.8K | -$129.3K | -$27.5K | $1.4M | -$75.0K | -$176.7K | |||
| Profit Loss Before Tax | -$9.0M | -$291.4K | $665.3K | -$864.2K | -$2.4M | -$9.5M | |||
| Income Tax Expense Continuing Operations | $1.7M | $370.9K | $245.4K | $150.5K | |||||
| Costs Of Service Revenues Earned | $206.7K | $308.6K | $154.4K | $271.2K | |||||
| Comprehensive Income Attributable To Noncontrolling Interests | $1.4M | -$75.0K | -$176.7K | ||||||
| Income Tax | $1.9M | $873.4K | $311.0K | $254.6K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2023 |
|---|---|
| Net Income * | $672.4K |
| General And Administrative Expense | $1.4M |
| Other Comprehensive Income | $678.5K |
| Gross Profit | $2.4M |
| Profit Loss From Operating Activities | $426.2K |
| Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity | $642.8K |
| Interest Expenses | $69.2K |
| Gross Profit Excluding Fair Value Items | $2.1M |
| Cost Of Finished Cannabis Inventory Sold | $1.4M |
| Comprehensive Income Attributable To Owners Of Parent | $648.9K |
| Profit Loss Attributable To Noncontrolling Interests | $29.6K |
| Profit Loss Before Tax | $1.1M |
| Income Tax Expense Continuing Operations | $383.5K |
| Costs Of Service Revenues Earned | $89.2K |
| Comprehensive Income Attributable To Noncontrolling Interests | |
| Income Tax |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents | $4.7M | $6.8M | $1.6M | $1.1M | $217.8K | $74.9K | $826.6K | $453.2K | $450.0K | $32.2K |
| Cash Flows From Used In Operating Activities | $7.1M | $5.7M | $2.0M | -$238.5K | -$292.8K | -$3.4M | -$2.4M | -$696.5K | -$438.6K | |
| Cash Flows From Used In Financing Activities | $3.0M | $4.4M | -$422.5K | $3.9M | $1.1M | $2.9M | $3.8M | $1.9M | $858.7K | |
| Unrealized Gain On Changes In Fair Value Of Biological Assets | $2.8M | $3.4M | $3.3M | $1.8M | $1.5M | -$486.4K | -$541.4K | -$985.5K | ||
| Realized Fair Value Amounts Included In Inventory Sold | $3.4M | $2.6M | $3.7M | $950.5K | $1.5M | $622.8K | $997.7K | |||
| Gains Losses On Disposals Of Property Plant And Equipment | $50.1K | -$182.0K | -$6.3K | -$7.5K | -$10.0K | -$70.4K | -$9.1K | |||
| Cash Flows From Used In Investing Activities | -$12.2M | -$2.9M | -$1.1M | -$2.7M | -$648.8K | -$261.2K | -$1.1M | -$764.2K | ||
| Repayment Of Longterm Debt1 | $1.2M | $1.6M | $732.8K | $507.7K | -$226.1K | -$250.1K | -$578.3K | -$17.9K | ||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $1.7M | $1.5M | $1.1M | $2.0M | $557.8K | $216.1K | $1.1M | $724.8K | ||
| Amortization Of Property And Equipment Included In Costs Of Inventory Sold | $2.0M | $1.8M | $1.1M | $733.7K | $519.0K | $191.1K | ||||
| Trade And Other Current Payables | $2.1M | $1.4M | $1.8M | $1.8M | $1.1M | $564.7K | $2.4M | $529.8K | ||
| Retained Earnings | -$32.8M | -$20.4M | -$21.4M | $21.8M | -$19.4M | -$17.1M | -$7.8M | -$302.4K | ||
| Liabilities | $27.4M | $16.3M | $7.4M | $7.1M | $4.7M | $4.4M | $5.6M | $529.8K | ||
| Equity And Liabilities | $43.3M | $29.6M | $16.4M | $14.2M | $3.8M | $2.9M | $5.4M | $42.0K | ||
| Current Liabilities | $20.0M | $11.8M | $5.3M | $3.9M | $1.8M | $4.1M | $3.3M | $529.8K | ||
| Current Assets | $20.7M | $15.6M | $7.9M | $6.7M | $1.8M | $1.4M | $2.9M | $42.0K | ||
| Assets | $43.3M | $29.6M | $16.4M | $14.2M | $3.8M | $2.9M | $5.4M | $42.0K | ||
| Property Plant And Equipments | $11.9M | $8.8M | $7.7M | $5.7M | $232.1K | $232.1K | $1.6M | |||
| Current Lease Liabilities | $736.5K | $926.0K | $1.0M | $624.9K | $355.7K | $129.9K | $99.1K | |||
| Biological Assets | $1.6M | $1.7M | $1.2M | $1.2M | $250.7K | $156.6K | $149.6K | $10.4K | ||
| Intangible Assets Other Than Goodwills | $1.3M | $725.7K | $725.7K | $399.3K | $5.0K | $34.6K | $65.0K | |||
| Equity Attributable To Owners Of Parent | $14.6M | $12.3M | $6.9M | $5.1M | -$911.6K | -$1.4M | -$247.6K | |||
| Account Receivable Net | $1.6M | $1.6M | $1.6M | $739.2K | $172.1K | $99.2K | $252.9K | |||
| Current Portion Of Longterm Debt | $227.7K | $780.4K | $1.8M | $843.9K | $46.1K | $150.0K | ||||
| Accumulated Other Comprehensive Income | -$125.9K | -$108.1K | -$109.6K | -$90.4K | -$12.2K | $121.9K | ||||
| Unrealized Loss On Derivative Liability | $12.8M | $4.6M | $1.3M | |||||||
| Non Current Longterm Debt | $1.0M | $82.3K | $839.2K | $1.4M | $753.7K | $50.0K | ||||
| Lease Liabilities | $4.5M | $2.0M | $1.3M | $1.7M | $16.6K | $12.3K | ||||
| Unrealized Fair Value Gain On Growth Of Biological Assets | $2.8M | $3.4M | $3.3M | $1.8M | ||||||
| Realized Fair Value Loss Amounts In Inventory Sold | $3.4M | $2.6M | $3.7M | $950.5K | ||||||
| Business Acquisition Consideration Payable | $536.9K | $360.0K | $360.0K | $358.5K | ||||||
| Unrealized Gain Loss On Fair Value Of Derivative Liability | -$12.8M | -$4.6M | -$1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2023 |
|---|---|
| Cash And Cash Equivalents | |
| Cash Flows From Used In Operating Activities | $231.1K |
| Cash Flows From Used In Financing Activities | -$1.1M |
| Unrealized Gain On Changes In Fair Value Of Biological Assets | $686.9K |
| Realized Fair Value Amounts Included In Inventory Sold | $460.6K |
| Gains Losses On Disposals Of Property Plant And Equipment | -$87.7K |
| Cash Flows From Used In Investing Activities | -$1.1M |
| Repayment Of Longterm Debt1 | $568.2K |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $126.7K |
| Amortization Of Property And Equipment Included In Costs Of Inventory Sold | $210.0K |
| Trade And Other Current Payables | |
| Retained Earnings | |
| Liabilities | |
| Equity And Liabilities | |
| Current Liabilities | |
| Current Assets | |
| Assets | |
| Property Plant And Equipments | |
| Current Lease Liabilities | |
| Biological Assets | |
| Intangible Assets Other Than Goodwills | |
| Equity Attributable To Owners Of Parent | |
| Account Receivable Net | |
| Current Portion Of Longterm Debt | |
| Accumulated Other Comprehensive Income | |
| Unrealized Loss On Derivative Liability | -$337.0K |
| Non Current Longterm Debt | |
| Lease Liabilities | |
| Unrealized Fair Value Gain On Growth Of Biological Assets | $686.9K |
| Realized Fair Value Loss Amounts In Inventory Sold | $460.6K |
| Business Acquisition Consideration Payable | |
| Unrealized Gain Loss On Fair Value Of Derivative Liability | $337.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$2.1M | $7.3M | $468.4K | $896.2K | $142.9K | -$751.7K | $373.4K | $453.2K | $420.1K |
| Payments Of Lease Principal | $974.7K | $1.7M | $1.1M | $380.5K | $372.2K | $117.1K | |||
| Proceeds From Longterm Debt | $100.0K | $1.1M | $615.0K | $100.0K | $2.6M | $1.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2023 |
|---|---|
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$2.1M |
| Payments Of Lease Principal | $444.3K |
| Proceeds From Longterm Debt |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Weighted Average Shares Outstanding Diluted | 237.4M | 172.7M | 169.2M | 135.2M | 5.3M | 2.7M | 2.1M |
| Weighted Average Shares Outstanding Basic | 209.4M | 172.7M | 169.2M | 135.2M | 5.3M | 2.7M | 2.1M |
| Gain Loss Per Share Attributable To Shareholders Diluted | $0.01 | $0.00 | $0.00 | $-0.02 | |||
| Gain Loss Per Share Attributable To Shareholders Basic | $0.05 | $0.00 | $0.00 | $-0.02 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2023 |
|---|---|
| Weighted Average Shares Outstanding Diluted | 214.0M |
| Weighted Average Shares Outstanding Basic | 182.0M |
| Gain Loss Per Share Attributable To Shareholders Diluted | $0.00 |
| Gain Loss Per Share Attributable To Shareholders Basic | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Key Management Personnel Compensation Sharebased Payment | $1.3M | $346.1K | $71.0K | $280.8K | $337.2K | $113.2K | $1.0M | $1.6M | $615.9K |
| Expense By Nature | $12.3M | $8.4M | $7.2M | $5.4M | $3.4M | $8.5M | $4.6M | $1.1M | |
| Amortization Of Property And Equipments | $939.7K | $578.6K | $750.9K | $180.0K | $250.8K | $63.3K | $460.0K | $45.9K | |
| Gains Losses On Exchange Differences On Translation Net Of Tax | -$17.9K | -$4.6K | -$19.2K | -$78.2K | -$134.1K | $121.9K | |||
| Noncash Items In Netloss | $5.7M | $6.4M | $3.2M | $1.9M | -$196.7K | -$3.9M | -$4.6M | -$1.2M | |
| Net Loss | $10.7M | $662.3K | -$420.0K | $1.0M | $2.4M | $9.5M | $7.5M | $302.4K | |
| Other Operating Income Expense | $1.9M | $441.5K | -$3.4K | -$17.1K | $14.8K | $16.7K | |||
| Accretions Expense | $2.0M | $1.0M | $491.8K | $949.8K | $569.0K | $153.2K | |||
| Changes In Noncash Working Capital Note21 | $1.4M | -$677.2K | -$1.2M | -$2.1M | -$96.1K | -$302.7K | $1.3M | ||
| Stock Option Expense | $1.3M | $344.6K | $96.6K | $243.7K | $174.9K | ||||
| Additional Paidin Capital | $9.0M | $8.2M | $6.5M | $6.4M | $4.1M | $2.9M | $2.0M | $5.2M | |
| Total Other Expense Net | $10.1M | -$4.5M | -$291.8K | -$1.6M | |||||
| Accretion Expenses | $1.0M | $491.8K | $949.8K | $609.4K | $153.2K | $317.8K | $33.2K | ||
| Inventories | $4.8M | $5.0M | $3.1M | $3.3M | $1.1M | $940.7K | $1.4M | ||
| Current Prepaid Expenses | $864.0K | $420.3K | $352.3K | $357.5K | $69.8K | $126.3K | $207.6K | ||
| Share Capital | $38.5M | $24.6M | $21.9M | $20.5M | $14.4M | $12.6M | |||
| Repayment Of Convertible Debentures | $522.0K | $261.0K | $1.3M | ||||||
| Currency Translation Gain Loss | -$17.9K | -$2.2K | $918.00 | $7.2K | |||||
| Stock Option Vesting Expense | $344.6K | $243.7K | |||||||
| Unrealized Gain On Warrants Asset | $3.1M | $129.1K | |||||||
| Sharesbased Compensation | 21.3K | 170.1K | 239.1K | 113.2K | 1.0M | ||||
| Noncontrolling Interest | $1.4M | $1.0M | $2.0M | $196.3K | |||||
| Currency Translation Adjustment | -$4.6K | -$19.2K | -$78.2K | -$134.1K | $121.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2023 |
|---|---|
| Key Management Personnel Compensation Sharebased Payment | $104.4K |
| Expense By Nature | $1.9M |
| Amortization Of Property And Equipments | $186.4K |
| Gains Losses On Exchange Differences On Translation Net Of Tax | $6.1K |
| Noncash Items In Netloss | $744.3K |
| Net Loss | -$672.4K |
| Other Operating Income Expense | $49.7K |
| Accretions Expense | $216.5K |
| Changes In Noncash Working Capital Note21 | -$513.2K |
| Stock Option Expense | $104.4K |
| Additional Paidin Capital | |
| Total Other Expense Net | $629.8K |
| Accretion Expenses | $216.5K |
| Inventories | |
| Current Prepaid Expenses | |
| Share Capital | |
| Repayment Of Convertible Debentures | $127.0K |
| Currency Translation Gain Loss | $6.1K |
| Stock Option Vesting Expense | $104.4K |
| Unrealized Gain On Warrants Asset | $400.0K |
| Sharesbased Compensation | |
| Noncontrolling Interest | |
| Currency Translation Adjustment |
Most recent annual filing with the SEC: April 30, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.